← All companies

LIMN

Liminatus Pharma, Inc.

LIMN Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$0.11

+0.01 +11.76%

Key statistics

from XBRL data in SEC filings

Market cap

$5.12M

Revenue (TTM)

—

Net income (TTM)

-$11.0M

EPS (TTM)

$-0.44

P/E ratio

—

Dividend yield

—

Free cash flow

-$9.98M

Cash

$0.00

Total assets

$2.79M

Gross margin

—

52-week range

$0.10 – $6.31

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Other events Jul 30, 2026 8-K Delisting notice or listing-rule failure; Other events Jul 24, 2026 8-K Entered a material agreement; Completed an acquisition or disposition; Unregistered sale of equity; Amended charter or bylaws Jul 6, 2026 8-K Entered a material agreement; Unregistered sale of equity; Modified rights of security holders; Other events Jun 3, 2026 8-K Delisting notice or listing-rule failure May 27, 2026 8-K Entered a material agreement May 20, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 10-K Fiscal year ended 2025-12-31 Mar 31, 2026 8-K Amended charter or bylaws Mar 4, 2026 8-K Entered a material agreement; Other events Feb 18, 2026 8-K Entered a material agreement; Unregistered sale of equity Feb 9, 2026 8-K Delisting notice or listing-rule failure Jan 26, 2026 8-K Delisting notice or listing-rule failure Nov 25, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 10-Q Quarter ended 2025-06-30 Oct 6, 2025 8-K Delisting notice or listing-rule failure Aug 25, 2025 8-K Regulation FD disclosure Aug 14, 2025 8-K Entered a material agreement; Unregistered sale of equity Jul 17, 2025 8-K Director or officer change Jul 11, 2025 8-K Other events Jul 3, 2025 8-K Regulation FD disclosure Jun 24, 2025 8-K Other events Jun 24, 2025 8-K Delisting notice or listing-rule failure Jun 4, 2025 10-Q Quarter ended 2025-03-31 Jun 2, 2025 8-K/A Completed an acquisition or disposition Jun 2, 2025 8-K Entered a material agreement; Completed an acquisition or disposition; Unregistered sale of equity; Modified rights of security holders; Changed accountants; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Item 5.06; Regulation FD disclosure; Other events May 6, 2025

Other filings

SCHEDULE 13G Jul 22, 2026 4 OWNERSHIP DOCUMENT Jul 14, 2026 SCHEDULE 13D/A Jul 14, 2026 DEF 14A Jul 13, 2026 4 OWNERSHIP DOCUMENT Jul 6, 2026 3 OWNERSHIP DOCUMENT Jul 6, 2026 SCHEDULE 13G/A Jul 6, 2026 PRE 14A Jun 30, 2026 S-1 Jun 24, 2026 D Item 06b Jun 18, 2026 424B3 Jun 3, 2026 SCHEDULE 13G Feb 20, 2026 424B4 Feb 18, 2026 EFFECT Feb 13, 2026